Advanced bladder cancer Advanced uterine cancer Recurrent rectal cancer
Conditions
Interventions
Establish isolated pelvic perfusion using balloon catheters. Perform the procedure more than twice, more than 2 weeks apart. Initial dose is cisplatin 190mg/m2 plus 5-FU 2000mg/m2 for bladder cancer,
Sponsors
Nippon medical school
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent 2. No indication of surgical resection 3. Apparent increase in tumor size after performing chemotherapy and radiation therapy according to a standard protocol 4. Performance status of 0-2 according to the Eastern Cooperative Oncology Group (ECOG) score 5. Acceptable renal function (serum creatinine less than 1.2 mg/dl) 6. Acceptable bone marrow function (leukocyte count 3500/mm3 or more, and platelet count 50000/mm3 or more).
Exclusion criteria
Exclusion criteria: 1. Contraindication to angiography (due to severe side effect of contrast media) 2. High risk for general anesthesia 3. Severe comorbidities 4. Vascular anatomy not suitable for catheterization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year survival rate Progression free survival Antitumor effect (RECIST) Adverse events (CTCAE grade) within 4 weeks after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Performance status Visual analog scale | — |
Countries
Japan,North America,Europe
Contacts
Public ContactSatoru Murata
Nippon medical school Department of Radiology
Outcome results
None listed